Accueil   Diary - News   All news Poxel Successfully Raises €17.7 Million in a Capital Increase and Announces Program Update and Preclinical Results on PXL770

Poxel Successfully Raises €17.7 Million in a Capital Increase and Announces Program Update and Preclinical Results on PXL770

Poxel Successfully Raises €17.7 Million in a Capital Increase

 

LYON, France--(BUSINESS WIRE)--POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH) (“Poxel”, or the “Company”), today announced the successful private placement of 2,358,483 new ordinary shares, each with a nominal value of €0.02 per share (the “New Shares”), reserved to a specified category of investors (the “Reserved Offering”). The gross proceeds of the Reserved Offering are €17,688,622.50 ($19.4 million).

 

Read the press release

 

Poxel Announces Program Update and Preclinical Results on PXL770 for NASH Combinations and Other Metabolic Diseases

 

LYON, France--(BUSINESS WIRE)-- POXEL SA, today announced new preclinical results for PXL770, the lead molecule in the Company’s adenosine monophosphate-activated protein kinase (AMPK) platform. PXL770, a directAMPK activator, was evaluated in a rodent NASH model in combination with other key agents in development, including an FXR agonist (obeticholic acid), a GLP-1 receptor agonist (semaglutide) and a thyroid receptor β agonist (MGL-3196). The results highlight PXL770 as a potentially novel NASH therapy that may also produce complementary benefits when combined with other agents with different mechanisms of action.

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree